<DOC>
	<DOCNO>NCT00617903</DOCNO>
	<brief_summary>This exploratory study perform determine whether new form formulation azelaic acid 15 % effective treatment papulopustular rosecea .</brief_summary>
	<brief_title>Exploration Safety Efficacy AzA 15 % Foam Twice Day Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<mesh_term>Azelaic acid</mesh_term>
	<criteria>male female patient least 18 year age sign informed consent Papulopustular rosacea minimum 10 maximum 50 papule and/or pustule , persistent erythema , telangiectasia Ability willingness accept comply treatment require medical examination Known nonresponders azelaic acid Erythematotelangiectatic , rhinophymatous , ocular , steroid rosacea Presence dermatosis could interfere rosacea diagnosis Treatment isotretinoin six month prior randomization Treatment face topical retinoids two week prior randomization Treatment oral antibiotic four week prior randomization Treatment topical antibiotic Treatment systemic corticosteroid 4 week prior randomization Treatment face topical corticosteroid 2 week prior randomization Treatment face topical imidazole antimycotic 2 week prior randomization Treatment face topical azelaic acid formulation 2 week prior randomization Use sauna 2 week prior randomization study Facial laser surgery telangiectasia 6 week prior randomization Planned concurrent use treatment study medication affect rosacea History hypersensitivity propylene glycol ingredient study drug Participation another clinical trial last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>rosacea</keyword>
	<keyword>papulopustular</keyword>
	<keyword>azelaic acid</keyword>
	<keyword>foam</keyword>
</DOC>